# A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.

> **NCT04808154** · PHASE1 · COMPLETED · sponsor: **Sinew Pharma Inc.** · enrollment: 28 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** SNP-630

## Key facts

- **NCT ID:** NCT04808154
- **Lead sponsor:** Sinew Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-22
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808154, "A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04808154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*